{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:56:42Z","timestamp":1771023402595,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"Austrian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004784","name":"Novartis Foundation for medical-biological research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008486","name":"Swiss Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jneuroim.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T14:29:52Z","timestamp":1549808992000},"page":"23-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["IVIG efficacy in CIDP patients is not associated with terminal complement inhibition"],"prefix":"10.1016","volume":"330","author":[{"given":"Christian W.","family":"Keller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaak","family":"Quast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2019.02.001_bb0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0010","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI114387","article-title":"Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a Guinea pig model","volume":"84","author":"Basta","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","article-title":"Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease","volume":"18","author":"Bruhns","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0030","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0045","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-5728(88)90101-4","article-title":"Immune reactive C3d on the surface of myelin sheaths in neuropathy","volume":"18","author":"Hays","year":"1988","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","article-title":"Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific fc receptors","volume":"203","author":"Kaneko","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0085","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"352","author":"K\u00f6ller","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0095","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1172\/JCI113231","article-title":"Activation of terminal components of complement in patients with Guillain-Barr\u00e9 syndrome and other demyelinating neuropathies","volume":"80","author":"Koski","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0105","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI118297","article-title":"Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation","volume":"96","author":"Magee","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0110","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation","volume":"80","author":"Mevorach","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semcdb.2017.06.009","article-title":"Molecular cell biology of complement membrane attack","volume":"72","author":"Morgan","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0120","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1212\/NXI.0000000000000148","article-title":"Deregulated Fc\u03b3 receptor expression in patients with CIDP","volume":"2","author":"Quast","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.331","article-title":"Terminal complement activation is increased and associated with disease severity in CIDP","volume":"3","author":"Quast","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0135","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0140","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0145","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0150","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/acn3.326","article-title":"Dose-dependent inhibition of demyelination and microglia activation by IVIG","volume":"3","author":"Winter","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2019.02.001_bb0155","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6610","article-title":"A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of Eculizumab in patients with Guillain-Barr\u00e9 syndrome (GBS): protocol of Japanese Eculizumab trial for GBS (JET-GBS)","volume":"5","author":"Yamaguchi","year":"2016","journal-title":"JMIR Res. Protoc."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818305034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818305034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:33:15Z","timestamp":1759048395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572818305034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":31,"alternative-id":["S0165572818305034"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.02.001","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IVIG efficacy in CIDP patients is not associated with terminal complement inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}